Role of the cyclooxygenase pathway in the protection against postischemic stunning in conscious sheep

Molecular and Cellular Biochemistry

Volumn 289, Issue 1-2, 2006, Pages 91-100

  Lascano, Elena C ^a   del Valle, Héctor F ^a   Negroni, Jorge A ^a  

^a FAVALORO UNIVERSITY   (Argentina)

Author keywords

Conscious sheep; Cyclooxygenase; Late preconditioning; Postischemic stunning

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENZYME INHIBITION; HEART INFARCTION PREVENTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; MALE; NONHUMAN; SHEEP; STATISTICAL SIGNIFICANCE; STUNNED HEART MUSCLE;

ANIMALS; CONSCIOUSNESS; CYCLOOXYGENASE 2; HEMODYNAMIC PROCESSES; HEMODYNAMICS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL STUNNING; SHEEP; TIME FACTORS;

ANIMALIA; OVIS ARIES;

EID: 33748333115     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-006-9152-4     Document Type: Article

References (42)

1. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 38: 97-120, 1998
2. Shinmura K, Tang XL, Wang Y, Xuan YT, Liu SQ, Takano H, Bhatnagar A, Bolli R: Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202, 2000
3. Adderley SR, Fitzgerald DJ: Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274: 5038-5046, 1999
4. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ: Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585-590, 2001
5. Guo Y, Bao W, Wu WJ, Shinmura K, Tang XL, Bolli R: Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol 95: 479-484, 2000
6. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A: Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol 37: 71-77, 2004
7. La Pointe MC, Mendez M, Leung A, Tao Z, Yang XP: Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 286: H1416-H1424, 2004
8. Scheuren N, Jacobs M, Ertl G, Schorb W: Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. J Mol Cell Cardiol 34: 1-3, 2002
9. Bombardier C, Laine L, Reicin A: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 343: 1520-1528, 2000
10. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Eng J Med 352: 1071-1080, 2005
11. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, Michel B, Luscher TF, Noll G, Ruschitzka F: Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409, 2003
12. Chyrchel M, Dudek D, Bartus S, Legutko J, Heba G, Dubiel JS: High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina. Kardiol Pol 61: 213-221, 2004
13. Shinmura K, Kodani E, Xuan YT, Dawn B, Tang XL, Bolli R: Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 41: 1183-1194, 2003
14. Lascano EC, Del Valle HF, Negroni JA: Effect of different doses of aspirin on preconditioning against stunning in conscious sheep. Medicina 64: 30-36, 2004
15. Paraskevaidis IA, Iliodromitis EK, Mavrogeni S, Karavolias GK, Theodorakis GN, Georgiadis M, Kremastinos DT: Repeated exercise stress identifies early and late preconditioning. Int J Cardiol 98: 221-226, 2005
16. Jneid H, Chandra M, Alshaher M, Hornung CA, Tang XL, Leesar M, Bolli R: Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation 111: 2565-2571, 2005
17. Negroni JA, Lascano EC, del Valle HF, Crottogini AJ: ATP-sensitive potassium channels do not have a main role in mediating late preconditioning protection against arrhythmias and stunning in conscious sheep. Basic Res Cardiol 97: 55-64, 2002
18. Del Valle HF, Lascano EC, Negroni JA, Crottogini AJ: Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc Res 50: 474-485, 2001
19. Del Valle HF, Lascano EC, Negroni JA: Ischemic preconditioning protection against stunning in conscious diabetic sheep: Role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res 55: 642-659, 2002
20. Del Valle HF, Lascano EC, Negroni JA, Crottogini AJ: Absence of ischemic preconditioning protection in diabetic sheep hearts: Role of sarcolemmal KATP channel dysfunction. Mol Cell Biochem 249: 21-30, 2003
21. Lascano EC, Negroni JA, Del Valle HF: Ischemic shortening of action potential duration as a result of KATP channel opening attenuates myocardial stunning by reducing calcium influx. Mol Cell Biochem 236: 53-61, 2002
22. Coceani F, Ackerley C, Seidlitz E, Kelsey L: Function of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the ductus arteriosus from foetal lamb: Differential development and change by oxygen and endotoxin. Br J Pharmacol 132: 241-251, 2001
23. Tai TC, Adamson SL: Developmental changes in respiratory, febrile, and cardiovascular responses to PGE(2) in newborn lambs. Am J Physiol Regul Integr Comp Physiol 278: R1460-R1473, 2000
24. Rossoni G, Muscara MN, Cirino G, Wallace JL: Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol 135: 1540-1546, 2002
25. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 363: 1751-1756, 2004
26. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 365: 475-481, 2005
27. Bernatsky S, Hudson M, Suissa S: Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 44: 677-680, 2005
28. Donato M, Gelpi RJ: Adenosine and cardioprotection during reperfusion-an overview. Mol Cell Biochem 251: 153-159, 2003
29. Barbieri SS, Eligini S, Brambilla M, Tremoli E, Colli S: Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte to macrophage differentiation; critical role of NADPH oxidase. Cardiovasc Res 60: 187-197, 2003
30. Mouithys-Mickalad A, Deby-Dupont G, Dogne JM, de Leval X, Kohnen S, Navet R, Sluse F, Hoebeke M, Pirotte B, Lamy M: Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1). Biochem Biophys Res Commun 325: 1122-1130, 2004
31. Papanastasiou S, Estdale SE, Homer-Vanniasinkam S, Mathie RT: Protective effect of preconditioning and adenosine pretreatment in experimental skeletal muscle reperfusion injury. Br J Surg 86: 916-922, 1999
32. St-Pierre AC, Cantin B, Bergeron J, Pirro M, Dagenais GR, Despres JP, Lamarche B: Inflammatory markers and long-term risk of ischemic heart disease in men A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 182: 315-321, 2005
33. Antonicelli R, Olivieri F, Bonafe M, Cavallone L, Spazzafumo L, Marchegiani F, Cardelli M, Recanatini A, Testarmata P, Boemi M, Parati G, Franceschi C: The interleukin-6-174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol 103: 266-271, 2005
34. Chen QH, Rao PN, Knaus EE: Design, synthesis, and biological evaluation of N-acetyl-2-carboxybenzenesulfonamides: A novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioog Med Chem 13: 2459-2468, 2005
35. Shinmura K, Nagai M, Tamaki K, Tani M, Bolli R: COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts. Am J Physiol Heart Circ Physiol 283: H2534-H2543, 2002
36. Jiang X, Shi E, Nakajima Y, Sato S, Ohno K, Yue H: Cyclooxygenase-1 mediates the final stage of morphine-induced delayed cardioprotection in concert with cyclooxygenase-2. J Am Coll Cardiol 45:1 707-1715, 2005
37. Camitta MGW, Gabel SA, Chulada P, Bradbury A, Langenbach R, Zeldin DC, Murphy E: Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 104: 2453-2458, 2001
38. Sun JZ, Tang XL, Park SW, Qiu Y, Turrens JF, Bolli R: Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J Clin Invest 97: 562-576, 1996
39. Bolli R, Shinmura K, Tang XL, Kodani E, Xuan YT, Guo Y, Dawn B: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519, 2002
40. Shinmura K, Xuan YT, Tang XL, Kodani E, Han H, Zhu Y, Bolli R: Inducible nitric oxide synthase modulates cyclooxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res 90: 602-608, 2002
41. Ali BH: Comparative pharmacokinetics of salicylate in camels, sheep and goats. Eur J Drug Metab Pharmacokinet 28: 125-128, 2003
42. Gres P, Schulz R, Jansen J, Umschlag C, Heusch G: Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. Cardiovasc Res 55: 626-632, 2002